- $4.41m
- -$2.50m
- $0.16m
- 50
- 28
- 40
- 33
Annual balance sheet for Virax Biolabs, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 10-K | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.023 | 0.018 | 0.022 | 9.35 | 3.59 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0 | 0.001 | 0 | — | 0.218 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 0.023 | 0.04 | 0.049 | 9.63 | 4.38 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | — | — | — | 1.1 |
| Net Intangible Assets | |||||
| Total Assets | 0.023 | 0.04 | 0.049 | 9.81 | 5.48 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.24 | 0.871 | 1.25 | 0.908 | 0.169 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.08 | 0.69 | 1.02 | 0.686 | 0.117 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -1.06 | -0.651 | -0.975 | 9.13 | 5.37 |
| Total Liabilities & Shareholders' Equity | 0.023 | 0.04 | 0.049 | 9.81 | 5.48 |
| Total Common Shares Outstanding |